Introduction

Tuberculosis (TB) has been the leading cause of death worldwide; an estimated one billion people have died from TB in the past 200 years\(^1\). Despite the global effort to control TB, it remains a massive threat to global health. In 2012, 8.6 million new TB cases, 1.3 million human immunodeficiency virus (HIV)–negative TB deaths, and 0.35 million HIV-positive TB deaths were reported\(^2\). To prevent and interrupt pulmonary tuberculosis (PTB) transmission, emphasis should be placed on the early detection, early initiation of appropriate treatment, and adequate infection control measures.

Almost all PTB cases are transmitted through the airborne route\(^3\). Several factors are known to contribute to the...
infectiousness of a PTB patient. Studies have reported that most PTB patients are no longer infectious after 2 weeks of treatment due to a reduction in coughing and a decrease in viable Mycobacterium tuberculosis (MTB), such that their infectiousness is 50-times less than before anti-TB medication initiation. In fact, several TB guidelines define the determining factor for becoming noninfectious, even for patients with smear-positive PTB without any risk factor for multi-drug resistant (DR) TB, as the administration of standard multidrug anti-TB therapy for 2–3 weeks.

However, the relative infectiousness is associated with positive sputum culture results and is highest when the smear results are also positive. Moreover, it is well known that 13%–41% of new TB cases are transmitted from smear-negative but culture-positive patients. Therefore, sputum culture status is the most reliable and useful indicator of a patient’s infectiousness. Fitzwater et al. reported that the median conversion time from culture-positivity to culture-negativity under anti-TB medication is 37 days, which is longer than previously reported.

An induced sputum (IS) specimen is more useful for pathogen detection in suspected PTB cases than a spontaneous sputum specimen. This is especially true when a patient’s spontaneous sputum specimen is smear microscopy negative, the patient is unable to expectorate spontaneously, or when the produced sputum is inadequate in amount or quality. Anderson et al. reported that the diagnostic accuracy of an IS specimen is equivalent to that of bronchoscopy for the diagnosis of smear-negative PTB.

The reduction in coughing after anti-TB therapy limits the effectiveness of spontaneous sputum specimen in evaluating the infectiousness of PTB. However, no study has evaluated the change in infectiousness of treated PTB patients using repeated IS samples. Therefore, the aim of this study was to evaluate the infectious period in PTB patients fully susceptible to isoniazid (INH), rifampicin (RIF), ethambutol (EMB), and pyrazinamide (PZA) using weekly serial IS specimens while receiving adequate standard anti-TB chemotherapy.

### Materials and Methods

#### 1. Study population and design

This was a retrospective study performed in a cohort of patients diagnosed with PTB between March 2013 and February 2015 at the Inje University Busan Paik Hospital (a 903-bed, university-affiliated, tertiary referral hospital in Busan, Republic of Korea). Since March 2013, IS has been performed for patients with presumptive and microbiologically confirmed PTB at our hospital in a single outpatient room, ventilated directly to the outside. The protocol for this study was approved by the Institutional Review Board of Busan Paik Hospital (IRB No. 15-0194) and allowed review and publication of information from patient records. Informed consent was waived owing to the retrospective nature of the study, and patient information was anonymized prior to analysis.

Consecutive patients aged >20 years with a PTB diagnosis, and undergoing an IS, were screened for this study. To evaluate the smear and culture conversion rates after the commencement of anti-TB medication in non-DR PTB patients, the enrollment criteria were: (1) patients diagnosed with microbiologically confirmed PTB and (2) patients who underwent IS before the PTB diagnosis and weekly thereafter for the first 6 weeks after the commencement of anti-TB medication. The exclusion criteria were: (1) patients who had received any anti-TB treatment before the baseline IS; (2) patients who received prior PTB treatment, defined as ≥1-month history of TB treatment; (3) patients with DR-PTB including resistance to INH, RIF, EMB, or PZA; (4) patients who had discontinued the standard anti-TB medication (containing INH, RIF, EMB, and PZA) due to adverse drug reactions including hepatitis and skin rash during the first 6 weeks.

#### 2. IS procedure

The IS procedure was performed by trained nurses in a procedure room in the outpatient unit. Each IS comprised three procedural steps: (1) administration of 2 mL of salbutamol via a mouthpiece using an ultrasonic nebulizer (Pari Boy SX, Pari GmbH, Starnberg, Germany), (2) administration of 20 mL of 3% hypertonic saline using a nebulizer over a period of 20 minutes, and (3) sample collection following spontaneous expectoration of 1–20 mL sputum over the next 10–30 minutes. IS was not performed in patients with a history of airway hyperresponsiveness or bronchoconstriction including asthma and chronic obstructive pulmonary disease, or an oxygen saturation level below 90% in ambient air, because of the possibility of deterioration of their condition.

#### 3. Microbiologic examination of IS

All IS specimens were processed and pretreated in accordance with the recommended standard techniques for mycobacterial examination of sputum samples. Acid-fast bacilli (AFB) smears of IS were examined following auramine-rhodamine fluorescence staining and graded on a scale of 0 to 4+. All IS specimens were simultaneously cultured on both solid media (SM) and liquid media (LM) using 3% Ogawa medium (Eiken Chemical, Tokyo, Japan) and the mycobacterial growth indicator tube 960 system (Becton Dickinson, Mountain View, CA, USA). All MTB isolates from the baseline IS specimens were sent for drug sensitivity testing to the Korean Institute of Tuberculosis (KIT), a World Health Organization-designated supranational reference laboratory. At KIT, resistance to anti-TB agents was defined as mycobacterial growth
above 1% in Löwenstein-Jensen medium, using the propor-
tional method.

4. Classification of parenchymal lesions in PTB

We identified the presence or absence of cavitation of PTB based on chest computed tomography (CT). The extent of the parenchymal lesion was categorized on the basis of the lobar involvement seen in the chest CT.

5. Data analysis

The results presented in the text and tables are expressed as median values and interquartile ranges or as numbers (%). The data were compared using the Mann-Whitney U test for continuous variables, and using the Pearson's chi-square test or Fisher exact test for categorical variables. Cumulative percentage curves of positive-to-negative culture conversion according to PTB patients' AFB smear status were generated us-

Table 1. Demographic and clinical characteristics of enrolled 35 patients diagnosed with PTB who underwent induced sputum culture for 6 consecutive weeks

| Characteristic                        | All patients (n=35) | Smear-positive PTB (n=22) | Smear-negative PTB (n=13) | p-value |
|---------------------------------------|---------------------|---------------------------|---------------------------|---------|
| Age, yr                               | 44.0 (32.0–58.0)    | 47.5 (28.5–62.25)         | 39.0 (32.5–56.5)          | 0.484   |
| Male                                  | 23 (65.7)           | 15 (68.2)                 | 8 (61.5)                  | 0.726   |
| BMI, kg/m²                            | 20.7 (18.9–22.8)    | 21.0 (19.0–22.9)          | 20.7 (18.0–22.9)          | 0.773   |
| Comorbidity                           |                     |                           |                           | 0.290   |
| Diabetes                              | 4 (11.4)            | 2 (9.0)                   | 2 (15.4)                  |         |
| Hypertension                          | 8 (22.9)            | 6 (27.3)                  | 2 (15.4)                  |         |
| Rheumatoid arthritis                  | 1 (2.9)             | 1 (4.5)                   | 0                         |         |
| Lupus                                 | 1 (2.9)             | 1 (4.5)                   | 0                         |         |
| Smoking history                       |                     |                           |                           | 0.126   |
| Never                                 | 17 (48.6)           | 8 (36.4)                  | 9 (69.2)                  |         |
| Former                                | 4 (11.4)            | 3 (13.6)                  | 1 (7.7)                   |         |
| Current                               | 14 (40.0)           | 11 (50.0)                 | 3 (23.1)                  |         |
| Extent of parenchymal lesions         |                     |                           |                           | 0.075   |
| One lobe involved                     | 7 (20.0)            | 2 (9.0)                   | 5 (38.5)                  |         |
| Multiple lobes involved               | 28 (80.0)           | 20 (90.9)                 | 8 (61.5)                  |         |
| Cavitation on chest CT                | 24 (68.6)           | 17 (77.3)                 | 7 (53.8)                  | 0.258   |
| Location of parenchymal lesions       |                     |                           |                           |         |
| Right upper lobe                      | 27 (77.1)           | 20 (90.9)                 | 7 (53.8)                  | 0.019   |
| Right middle lobe                     | 3 (8.6)             | 3 (13.6)                  | 0                         | 0.279   |
| Right lower lobe                      | 23 (65.7)           | 14 (63.6)                 | 9 (69.2)                  | >0.990  |
| LUL (upper division of LUL)           | 22 (62.9)           | 15 (68.2)                 | 7 (53.8)                  | 0.480   |
| Left middle lobe (lingula)            | 2 (5.7)             | 2 (9.1)                   | 0                         | 0.519   |
| Left lower lobe                       | 15 (42.9)           | 11 (50.0)                 | 4 (30.8)                  | 0.312   |
| AFB smear status                      |                     |                           |                           |         |
| Positive                              | 22 (62.6)           | 22                        | -                         |         |
| 4+                                    | 7                   | 7                         | -                         |         |
| 3+                                    | 5                   | 5                         | -                         |         |
| 2+                                    | 6                   | 6                         | -                         |         |
| 1+                                    | 4                   | 4                         | -                         |         |
| Negative                              | 13 (37.1)           | -                         | 13                        |         |

Values are presented as number of patients (%) or median (interquartile range).

PTB: pulmonary tuberculosis; BMI: body mass index; CT: computed tomography; LUL: left upper lobe; AFB: acid-fast bacilli.
ing the Kaplan-Meier method and the curves were compared using the log-rank test. All comparisons were two-sided, and a p-value <0.05 was considered to indicate statistical significance. Data were analyzed using IBM SPSS Statistics version 19 (IBM Corp., Armonk, NY, USA).

Results

1. Patient characteristics

During the study period, 773 patients were diagnosed with PTB. Of these, 41 patients underwent IS before the PTB diagnosis and a weekly IS thereafter for the first 6 weeks of receiving anti-TB medication. Six patients were excluded because they had DR-PTB (two resistant to INH only, one resistant to INH and EMB, and one resistant to RIF and EMB or because they had discontinued anti-TB medication because of hepatitis [n=1] or skin rash [n=1]). Finally, 35 PTB patients were included in the study and analyzed. The demographic and descriptive data of the enrolled patients are summarized in Table 1. Of the 35 enrolled PTB patients, 22 (63%) were AFB smear-positive and the remaining 13 (37%) were AFB smear-negative. The enrolled patients were predominantly male and were classified as having PTB with multilobar involvement. None of the enrolled patients were co-infected with HIV.

2. Overall trend of positive-to-negative culture conversion assessed by weekly IS after commencement of appropriate standard anti-TB medication

The overall trend of positive-to-negative culture conversion in the 35 enrolled patients is shown in Figure 1A. After 2 weeks of anti-TB medication, 86% and 37% of the patients remained culture-positive for MTB in LM and SM, respectively. After 4 and 6 weeks, 49% and 6% of the cultures in LM and 9% and 0% of the cultures in SM were positive for MTB. The median conversion time from culture positivity to culture negativity for all patients was 28.0 days (range, 21.0–35.0 days).

3. Positive-to-negative culture conversion trend based on AFB smear status, as assessed using weekly IS specimens

Figure 1B and C show the different rates of conversion of PTB to culture negative according to AFB smear status, smear positive or smear negative. The results for the 22 smear-positive PTB patients in Figure 1B show that all patients remained culture positive in LM and 50% remained positive in SM after 2 weeks of appropriate anti-TB medication. Weekly serial IS specimens revealed that despite 4 and 6 weeks of appropriate therapy, 16 (73%) and two (9%) patients remained culture-positive for MTB in LM, respectively while two (9%) and 0 (0%) remained culture-positive in SM, respectively. The median conversion time for the enrolled smear-positive PTB patients to become culture-negative was 35.0 days (range, 28.0–42.0 days). We further assessed the changes in smear microscopy status based on the duration of administered therapy, and as depicted in Figure 1B the smear positivity rates over time were 82%, 50%, 32%, 32%, 32%, and 18%, respectively.

Of the 13 smear-negative PTB patients, 10 (77%) remained culture-positive for MTB in LM, and two (15%) remained positive in SM after 2 weeks of anti-TB medication, as shown in Figure 1C. After 4 weeks of anti-TB medications, one patient...
(8%) was culture-positive for MTB in LM and none of the 13 patients tested culture-positive in SM. Six weeks after anti-TB therapy initiation, none of the smear-negative PTB patients remained culture-positive in either LM or SM. The median time to conversion for smear-negative PTB patients was 21.0 days (range, 17.5–28.0 days).

We further generated curves for the cumulative percentages of positive-to-negative culture conversions in PTB patients after appropriate standard anti-TB medication according to their AFB smear status but regardless of whether the samples were cultured in SM or LM. As depicted in Figure 2, the percentages of culture conversion were significantly different between patients with smear-positive and smear-negative PTB (p<0.001).

**4. Overall rate of positive-to-negative culture conversion rates, independent of basal IS, following 4 weeks of anti-TB medication**

We next estimated the overall positive-to-negative culture conversion rates in our PTB cohort after 4 weeks of therapy by assessing the IS specimens. We performed this analysis for all patients who had an IS specimen available for the fourth week of medication, regardless of whether a basal IS was performed in them. Eighty-three PTB cases were analyzed including the 35 PTB cases that formed our study cohort. The 48 additional cases were selected based on the study's inclusion and exclusion criteria with two points of difference: first, these patients did not undergo IS at the time of PTB diagnosis, and second, they did not undergo weekly IS. PTB was microbiologically confirmed for all 48 cases using bronchoscopy (n=27) or spontaneous sputum (n=21) specimens at the time of diagnosis. The characteristics of the all 83 patients are described in Table 2. Figure 3 shows the proportion of patients who converted to culture-negative after 4 weeks of anti-TB medication. As shown in Figure 3B, 81% of the 31 smear-positive PTB patients remained culture-positive in LM, and 10% remained culture-positive in SM. Further, of the 52 patients with smear-negative PTB, 2% remained culture-positive in LM, and none were culture-positive in SM, as shown in Figure 3C.

**Discussion**

To the best of our knowledge, this is the first study to evaluate the infectious period of non-DR PTB patients after appropriate standard anti-TB medication, based on the conversion of weekly serial IS specimens to MTB culture-negative. In this study of 35 patients undergoing therapy for PTB, we found that most of these non-DR PTB patients remained culture positive after 2 weeks, although they had previously been considered non-infectious after 2 weeks of treatment. Moreover, more prolonged culture positivity was observed, even in smear-negative PTB patients, than would normally be expected. In particular, more than half of the smear-positive PTB patients remained culture-positive even after 4 weeks of treatment.

It has been postulated that to prevent PTB transmission, and by extension, to reduce the incidence of PTB, an adequate period of isolation is needed for PTB patients. Previous studies reported that an average 2 weeks of treatment with the standard combination of anti-TB medication resulted in a rapid decline in infectiousness, following which, patients were no longer considered infectious. Based on these stud-

**Table 2.** Clinical characteristics of 83 patients diagnosed with pulmonary TB who underwent induced sputum culture after 4 weeks of anti-TB medication, regardless of the basal induced sputum results

| Characteristic          | Value (n=83) |
|------------------------|--------------|
| Age, yr                | 52.0 (38.5–63.0) |
| Males                  | 60 (72.2) |
| Cavitation on radiography* | 41 (49.4) |
| Baseline respiratory specimen |           |
| Induced sputum         | 35 (42.1) |
| Spontaneous sputum     | 21 (25.3) |
| Bronchoscopy specimen  | 27 (32.5) |
| AFB smear status       |              |
| Positive               | 31 (37.3) |
| Negative               | 52 (62.7) |

Values are presented as number of patients (%) or median (interquartile range).
*The presence or absence of cavitation was determined based on chest X-ray.
TB: tuberculosis; AFB: acid-fast bacilli.
ies, many published guidelines recommend that 2 weeks of anti-TB therapy is sufficient to reduce infectiousness to a level where isolation is no longer required, although confirmation is not possible until smears are also negative for AFB\textsuperscript{3,13,14}. However, some recent studies have suggested that this belief may be incorrect. One study showed that 36.7% of HIV-negative and 27.2% HIV-positive smear-positive PTB patients were still AFB positive by sputum microscopy after 2 weeks of adequate therapy\textsuperscript{29}. Dominguez-Castellano et al.\textsuperscript{30} reported that the median time to conversion to an AFB-negative smear was 28.6 days and that this time was principally dependent on the presence of cavitation, although 12.8% patients in that study had DR-PTB. Parikh et al.\textsuperscript{31} reported that the median time to conversion of 71 smear-positive PTB patients to negative smear and culture was 5 weeks and 6.5 weeks, respectively. However, because they did not determine the presence of DR-PTB and cultured only on SM, these results may have limited applicability.

Rueda et al.\textsuperscript{32} reported that in a group of 72 prisoners the median time to smear and culture conversion assessed by monthly spontaneous sputum samples was 33 days and 59 days, respectively. In that study, 4.2% of the patients had DR-PTB. Furthermore, Fitzwater et al.\textsuperscript{18} reported that for the 67 non-DR PTB patients in their study cohort, the median time to become culture-negative, assessed using weekly spontaneous sputum samples, was 37 days.

The present study has several important findings because, unlike previous studies, we evaluated the infectiousness of PTB patients using IS. The results of previous studies suggested that the average infectious period for smear-positive PTB was approximately 30 days\textsuperscript{28}. However, as assessed by IS, 73\%--81\% of the patients with smear-positive PTB remained culture-positive after 4 weeks of anti-TB treatment. In addition, even in patients with smear-negative PTB, 76.9\% remained culture-positive after 2 weeks of therapy, although almost all of them became culture negative after 4 weeks of therapy. Owing to the contribution of smear-negative PTB patients towards TB transmission, this unexpectedly long infectious period of smear-negative PTB is especially noteworthy.

There are several known factors associated with the likelihood that a PTB patient will infect others, including the extent and severity of disease, frequency of coughing, the quality, and volume of respiratory secretions, anti-TB therapy, and the characteristics of exposure\textsuperscript{4}. Among these, cough is regarded as the predominant factor affecting PTB transmission and may be gradually decreased by chemotherapy\textsuperscript{33,34}. However, the direct measurement of the human-to-human transmission of PTB is complex and difficult\textsuperscript{35}. Moreover, convincing data on the effectiveness of masks and cough hygiene in reducing PTB transmission are few, although they are widely used protection measures\textsuperscript{35}. Therefore, microbiological criteria based on sputum analysis, such as conversion to culture-negative, have traditionally been used in clinical practice to determine PTB treatment success and infection control decisions\textsuperscript{33}.

There are several limitations to this study. First, infectiousness is not determined only by the presence of viable MTB in respiratory specimens of PTB patients, and thus our results may not be generalizable. Although the presence of viable MTB in respiratory specimens is meaningful, cough and volume of respiratory secretion are also important modes of transmission, but these may be reduced after adequate therapy. Second, weekly IS in PTB cases is not common prac-
tice in clinical settings; therefore, our serial IS specimen based results may not be generalizable. In our institution, a separate, isolated single outpatient room for IS specimen collection has been available since March 2013. At that time, only one isolated negative-pressure room in ward was available since our institution was under construction for remodeling. Thus, it was needed to evaluate whether PTB patients required isolation as precaution against airborne transmission, especially from smear-positive PTB cases. In smear-negative PTB patients, we conducted IS before releasing them from isolation (after initiation of anti-TB medication), or when TB patients wanted to know their infectiousness status. Third, this study is a retrospective hospital patient-based study with a small sample size. Fourth, due to the retrospective nature, we cannot present results from more than 7 weeks after commencement of therapy. Moreover, we could not evaluate the relationship between negative culture conversion of IS and other factors known to affect infectiousness, such as the extent of disease or cavitation, due to the small sample size. Lastly, this study was not conducted under directly observed therapy, which may also have influenced the study results.

Despite these limitations, this study may be valuable, as it assessed negative smear and culture conversion duration based on not only serial IS but also using LM and SM. The accurate evaluation of infectiousness of PTB would not be easy in real world. So, we think and hope, this study may provide additional information and be helpful for PTB control.

In conclusion, our study demonstrates that the conversion time from culture positivity to culture negativity is longer than previously thought, even in patients with drug-susceptible PTB. Furthermore, many patients with smear-negative PTB, and of course patients with smear-positive PTB, remained culture-positive after 2 weeks of appropriate anti-TB therapy. Although further evaluation is needed, this long period of culture positivity in PTB has practical implications for TB control and will aid in optimizing the isolation period during anti-TB medication.

Conflicts of Interest

No potential conflict of interest relevant to this article was reported.

Acknowledgments

The authors thank Ms. Sula Kim for her help in data collection.

References

1. Paulson T. Epidemiology: a mortal foe. Nature 2013;502:S2-3.
2. Eurosurveillance editorial team. WHO publishes Global tuberculosis report 2013. Euro Surveill 2013;18:20615.
3. American Thoracic Society; Centers for Disease Control and Prevention; Infectious Diseases Society of America. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: controlling tuberculosis in the United States. Am J Respir Crit Care Med 2005;172:1169-227.
4. Luna JA. A tuberculosis guide for specialist physicians. Paris: International Union Against Tuberculosis and Lung Disease; 2003.
5. Riley RL, Mills CC, O’Grady F, Sultan LU, Wittstadt F, Shivpuri DN. Infectiousness of air from a tuberculosis ward: ultraviolet irradiation of infected air; comparative infectiousness of different patients. Am Rev Respir Dis 1962;85:511-25.
6. Yeager H Jr, Lacy J, Smith LR, LeMaistre CA. Quantitative studies of mycobacterial populations in sputum and saliva. Am Rev Respir Dis 1967;95:998-1004.
7. Loudon RG, Spohn SK. Cough frequency and infectivity in patients with pulmonary tuberculosis. Am Rev Respir Dis 1969;99:109-11.
8. Sultan L, Nyka W, Mills C, O’Grady F, Wells W, Riley RL. Tuberculosis disseminators: a study of the variability of aerial infectivity of tuberculous patients. Am Rev Respir Dis 1960;82:358-69.
9. Jindani A, Aber VR, Edwards EA, Mitchison DA. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis 1980;121:939-49.
10. Brooks SM, Lassiter NL, Young EC. A pilot study concerning the infection risk of sputum positive tuberculosis patients on chemotherapy. Am Rev Respir Dis 1973;108:799-804.
11. Rouillon A, Perdrizet S, Parrot R. Transmission of tubercle bacilli: the effects of chemotherapy. Tubercole 1975;57:275-99.
12. National Collaborating Centre for Chronic Conditions; Centre for Clinical Practice at NICE. National Institute for Health and Clinical Excellence: guidance. Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control. London: National Institute for Health and Clinical Excellence; 2011.
13. National Tuberculosis Controllers Association; Centers for Disease Control and Prevention (CDC). Guidelines for the investigation of contacts of persons with infectious tuberculosis: recommendations from the National Tuberculosis Controllers Association and CDC. MMWR Recomm Rep 2005;54:1-47.
14. Public Health Agency of Canada; Canadian Lung Association; Canadian Thoracic Society. Canadian tuberculosis standards 7th edition. Ottwa: Public Health Agency of Canada, Canadian Lung Association, Canadian Thoracic Society; 2013.
15. Behr MA, Warren SA, Salamon H, Hopewell PC, Ponce de
Leon A, Daley CL, et al. Transmission of *Mycobacterium tuberculosis* from patients smear-negative for acid-fast bacilli. Lancet 1999;353:444-9.

16. Hernandez-Garduno E, Cook V, Kunimoto D, Elwood RK, Black WA, FitzGerald JM. Transmission of tuberculosis from smear negative patients: a molecular epidemiology study. Thorax 2004;59:286-90.

17. Tostmann A, Kik SV, Kalisvaart NA, Sebek MM, Verver S, Boeree MJ, et al. Tuberculosis transmission by patients with smear-negative pulmonary tuberculosis in a large cohort in the Netherlands. Clin Infect Dis 2008;47:1135-42.

18. Fitzwater SP, Caviedes L, Gilman RH, Coronel J, LaChira D, Salazar C, et al. Prolonged infectiousness of tuberculosis patients in a directly observed therapy short-course program with standardized therapy. Clin Infect Dis 2010;51:371-8.

19. Park JS. Efficacy of induced sputum for the diagnosis of pulmonary tuberculosis in adults unable to expectorate sputum. Tuberc Respir Dis 2013;78:203-9.

20. Gonzalez-Angulo Y, Wiysonge CS, Geldenhuys H, Hanekom W, Mahomed H, Hussey G, et al. Sputum induction for the diagnosis of pulmonary tuberculosis: a systematic review and meta-analysis. Eur J Clin Microbiol Infect Dis 2012;31:1619-30.

21. Hepple P, Ford N, McNerney R. Microscopy compared to culture for the diagnosis of tuberculosis in induced sputum samples: a systematic review. Int J Tuberc Lung Dis 2012;16:579-88.

22. Anderson C, Inhaber N, Menzies D. Comparison of sputum induction with fiber-optic bronchoscopy in the diagnosis of tuberculosis. Am J Respir Crit Care Med 1995;152:1570-4.

23. Grant LR, Hammitt LL, Murdoch DR, O'Brien KL, Scott JA. Procedures for collection of induced sputum specimens from children. Clin Infect Dis 2012;54 Suppl 2:S140-5.

24. Brown M, Varia H, Bassett P, Davidson RN, Wall R, Pasvol G. Prospective study of sputum induction, gastric washing, and bronchoalveolar lavage for the diagnosis of pulmonary tuberculosis in patients who are unable to expectorate. Clin Infect Dis 2007;44:1415-20.

25. Geldenhuys HD, Kleynhans W, Buckerfield N, Tameris M, Gonzalez Y, Mahomed H, et al. Safety and tolerability of sputum induction in adolescents and adults with suspected pulmonary tuberculosis. Eur J Clin Microbiol Infect Dis 2012;31:529-37.

26. Bae E, Im JH, Kim SW, Yoon NS, Sung H, Kim MN, et al. Evaluation of combination of BACTEC mycobacteria growth indicator tube 960 system and Ogawa media for mycobacterial culture. Korean J Lab Med 2008;28:299-306.

27. Diagnostic Standards and Classification of Tuberculosis in Adults and Children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999. Am J Respir Crit Care Med 2000;161:1376-95.

28. Yimer SA, Holm-Hansen C, Storla DG, Bjune GA. Tuberculosis management time: an alternative parameter for measuring the tuberculosis infectious pool. Trop Med Int Health 2014;19:313-20.

29. Senkoro M, Mfinanga SG, Morkve O. Smear microscopy and culture conversion rates among smear positive pulmonary tuberculosis patients by HIV status in Dar es Salaam, Tanzania. BMC Infect Dis 2010;10:210.

30. Dominguez-Castellano A, Muniaín MA, Rodríguez-Bano J, García M, Rios MJ, Gálvez J, et al. Factors associated with time to sputum smear conversion in active pulmonary tuberculosis. Int J Tuberc Lung Dis 2003;7:432-8.

31. Parikh R, Nataraj G, Kanade S, Khatri V, Mehta P. Time to sputum conversion in smear positive pulmonary TB patients on category I DOTS and factors delaying it. J Assoc Physicians India 2012;60:22-6.

32. Rueda ZV, Lopez L, Velez LA, Marin D, Giraldos MR, Pulido H, et al. High incidence of tuberculosis, low sensitivity of current diagnostic scheme and prolonged culture positivity in four colombian prisons. A cohort study. PLoS One 2013;8:e80592.

33. Aoki M. Transmission of tuberculosis (1). Kekkaku 2004;79:509-18.

34. Hales CM, Heilig CM, Chaisson R, Leung CC, Chang KC, Goldberg SV, et al. The association between symptoms and microbiologically defined response to tuberculosis treatment. Ann Am Thorac Soc 2013;10:18-25.

35. Turner RD, Bothamley GH. Cough and the transmission of tuberculosis. J Infect Dis 2015;211:1367-72.